Chongqing Genrix Biopharmaceutical Co., Ltd.

The company was founded in 2015 and is located in Chongqing International Biotechnology City. It is an innovative biopharmaceutical company driven by antibody drug discovery technology, focusing on treatment fields such as autoimmune diseases, infectious diseases, and tumors, and is engaged in R&D, production and commercialization of antibody drugs. The company's main business is R&D, production and sales of antibody drugs. The company's main products are Celizumab (GR1501), GR1802, GR1603, GR1801, GR2001, GR1803, etc. Company honors: Chongqing's “Specialized, Special and New” Enterprise, Big Data Application Demonstration Enterprise, Zhongtiancoin High-tech Enterprise, etc.